Addimmune's CEO on how the company is trying to harness modifying miRNAs to create a functional cure for HIV

blonca9
Jan 18, 2024
1 min read

Jeff Galvin explains how previous attempts at modifying CCR5 in T-cells have taught his company to more precisely target HIV and from additional angles.

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

Addimmune's CEO on how the company is trying to harness modifying miRNAs to create a functional cure for HIV

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight